Literature DB >> 11826205

A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation.

Manuel Durand1, Maria E Mendoza, Phuket Tantivit, Amir Kugelman, Cindy McEvoy.   

Abstract

OBJECTIVE: Dexamethasone is used in very low birth weight (VLBW) ventilator-dependent infants to prevent or decrease the severity of chronic lung disease. We reported a significant increase in respiratory compliance during a 7-day weaning course of moderately early dexamethasone therapy (0.5 mg/kg/d) in VLBW infants, along with a shorter duration of mechanical ventilation and O2 supplementation. Although 0.5 mg/kg/d has been the most commonly used dose in preterm infants, the use of a lower dose of dexamethasone may reduce potential adverse effects of steroid therapy. Quantification of dynamic pulmonary mechanics in VLBW infants who receive low-dose dexamethasone has not been reported. The objective of this study was to compare the effect of 2 dose regimens of dexamethasone on dynamic pulmonary mechanics, mean airway pressure (MAP), and fractional inspired oxygen concentration (Fio2) in intubated VLBW infants who were at risk for chronic lung disease.
METHODS: We studied 47 VLBW (birth weight: 550-1290 g; gestational age: 24-30 weeks) ventilator-dependent infants at 7 to 14 days of age. Twenty-three infants were randomized to receive dexamethasone at 0.5 mg/kg/d intravenously for 3 days (high dose), 0.25 mg/kg/d for 3 days, and 0.1 mg/kg/d during the 7th day; 24 infants received low-dose dexamethasone as 0.2 mg/kg/d for 3 days and 0.1 mg/kg/d for 4 days. Respiratory compliance (Crs) and resistance were measured before and on days 2, 5, and 7 of dexamethasone therapy. We recorded airway pressure, flow, and tidal volume, and mechanical breaths were analyzed.
RESULTS: Crs significantly increased during dexamethasone therapy in both groups of infants when compared with baseline (74% increase in the high-dose group and 66% increase in the low-dose group). Dexamethasone increased tidal volume and significantly reduced Fio2 and MAP in both groups of infants. A transient increase in blood pressure was noted in both groups.
CONCLUSIONS: Our findings indicate that 1) comparable significant increases in Crs are present in the low-dose dexamethasone as well as the high-dose dexamethasone groups on days 2, 5, and 7 of steroid therapy; and 2) MAP and Fio2 are significantly decreased during dexamethasone therapy in both groups of infants. We conclude that low-dose and high-dose dexamethasone, as used in this study, have comparable beneficial effects on dynamic pulmonary mechanics and subsequently on oxygen requirement and applied ventilatory support in VLBW infants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826205     DOI: 10.1542/peds.109.2.262

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

Review 1.  Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use.

Authors:  David G Grier; Henry L Halliday
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Anne Pmc De Jaegere; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

3.  Postnatal glucocorticoid-induced hypomyelination, gliosis, and neurologic deficits are dose-dependent, preparation-specific, and reversible.

Authors:  Muhammad T K Zia; Govindaiah Vinukonda; Linnea R Vose; Bala B R Bhimavarapu; Sanda Iacobas; Nishi K Pandey; Ann Marie Beall; Preeti Dohare; Edmund F LaGamma; Dumitru A Iacobas; Praveen Ballabh
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

Review 4.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

5.  Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial.

Authors:  Cindy McEvoy; Diane Schilling; Dawn Peters; Carrie Tillotson; Patricia Spitale; Linda Wallen; Sally Segel; Susan Bowling; Michael Gravett; Manuel Durand
Journal:  Am J Obstet Gynecol       Date:  2010-03-15       Impact factor: 8.661

6.  Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants.

Authors:  E S Shinwell; L Lerner-Geva; A Lusky; B Reichman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-06-12       Impact factor: 5.747

Review 7.  The Natural History of Bronchopulmonary Dysplasia: The Case for Primary Prevention.

Authors:  Cindy T McEvoy; Judy L Aschner
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

Review 8.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24

Review 9.  An Official American Thoracic Society/European Respiratory Society Workshop Report: Evaluation of Respiratory Mechanics and Function in the Pediatric and Neonatal Intensive Care Units.

Authors:  Stacey Peterson-Carmichael; Paul C Seddon; Ira M Cheifetz; Inéz Frerichs; Graham L Hall; Jürg Hammer; Zoltán Hantos; Anton H van Kaam; Cindy T McEvoy; Christopher J L Newth; J Jane Pillow; Gerrard F Rafferty; Margaret Rosenfeld; Janet Stocks; Sarath C Ranganathan
Journal:  Ann Am Thorac Soc       Date:  2016-02

10.  Postnatal corticosteroids for bronchopulmonary dysplasia.

Authors:  Alan H Jobe
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.